| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 10,632 | 13,817 | 158,569 | 4,894 |
| General and administrative | - | 15,262 | 14,653 | 12,692 |
| Research and development | 37,696 | 25,855 | 32,676 | 22,205 |
| Sales, general and administrative | 16,027 | - | - | - |
| Total operating expenses | 53,723 | 41,117 | 47,329 | 34,897 |
| Income (loss) from operations | -43,091 | -27,300 | 111,240 | -30,003 |
| Interest income (expense), net | 3,463 | 3,789 | 2,889 | 3,545 |
| Other income (expense), net | 3 | 28 | 28 | 28 |
| Total other income (expense) | 3,466 | 3,817 | 2,917 | 3,573 |
| Income (loss) before income taxes | -39,625 | -23,483 | 114,157 | - |
| Provision for income taxes | -1,278 | 0 | 1,278 | - |
| Net income (loss) | -38,347 | -23,483 | 112,879 | -26,430 |
| Unrealized gain on marketable securities | 350 | 200 | 47 | 181 |
| Total other comprehensive gain | 350 | 200 | 47 | 181 |
| Comprehensive income (loss) | -37,997 | -23,283 | 112,926 | -26,249 |
| Earnings per share, basic, total | -0.65 | -0.4 | 1.95 | -0.47 |
| Earnings per share, diluted, total | -0.65 | -0.4 | 1.9 | -0.47 |
| Weighted average number of shares outstanding, basic, total | 58,611,677 | 58,353,855 | 57,862,674 | 56,341,074 |
| Weighted average number of shares outstanding, diluted, total | 58,611,677 | 58,353,855 | 59,398,600 | 56,341,074 |
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)